

0570
0702

8



ENTERED

OIPE

RAW SEQUENCE LISTING

DATE: 07/10/2002

PATENT APPLICATION: US/10/066,009A

TIME: 13:07:38

Input Set : A:\P1869R1.txt

Output Set: N:\CRF3\07102002\J066009A.raw

3 <110> APPLICANT: Schaffer, Michelle
4 Ultsch, Mark
5 Vajdos, Felix
7 <120> TITLE OF INVENTION: CRYSTALLIZATION OF IGF-1
9 <130> FILE REFERENCE: P1869R1
11 <140> CURRENT APPLICATION NUMBER: US 10/066,009A
C--> 12 <141> CURRENT FILING DATE: 2002-06-24
14 <150> PRIOR APPLICATION NUMBER: US 60/287,072
15 <151> PRIOR FILING DATE: 2001-04-27
17 <150> PRIOR APPLICATION NUMBER: US 60/267,977
18 <151> PRIOR FILING DATE: 2001-02-09
20 <160> NUMBER OF SEQ ID NOS: 5
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 70
24 <212> TYPE: PRT
25 <213> ORGANISM: Homo sapiens
27 <400> SEQUENCE: 1
28 Gly Pro Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln
29 1 5 10 15
31 Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly
32 20 25 30
34 Tyr Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr Gly Ile Val Asp
35 35 40 45
37 Glu Cys Cys Phe Arg Ser Cys Asp Leu Arg Arg Leu Glu Met Tyr
38 50 55 60
40 Cys Ala Pro Leu Lys Pro Ala Lys Ser Ala
41 65 70
43 <210> SEQ ID NO: 2
44 <211> LENGTH: 67
45 <212> TYPE: PRT
46 <213> ORGANISM: Homo sapiens
48 <400> SEQUENCE: 2
49 Ala Tyr Arg Pro Ser Glu Thr Leu Cys Gly Gly Glu Leu Val Asp
50 1 5 10 15
52 Thr Leu Gln Phe Val Cys Gly Asp Arg Gly Phe Tyr Phe Ser Arg
53 20 25 30
55 Pro Ala Ser Arg Val Ser Arg Arg Ser Arg Gly Ile Val Glu Glu
56 35 40 45
58 Cys Cys Phe Arg Ser Cys Asp Leu Ala Leu Leu Glu Thr Tyr Cys
59 50 55 60
61 Ala Thr Pro Ala Lys Ser Glu
62 65
64 <210> SEQ ID NO: 3

RAW SEQUENCE LISTING

DATE: 07/10/2002

PATENT APPLICATION: US/10/066,009A

TIME: 13:07:38

Input Set : A:\P1869R1.txt

Output Set: N:\CRF3\07102002\J066009A.raw

```

65 <211> LENGTH: 50
66 <212> TYPE: PRT
67 <213> ORGANISM: Homo sapiens
69 <400> SEQUENCE: 3
70 Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu
71 1 5 10 15
73 Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Gly
74 20 25 30
76 Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu
77 35 40 45
79 Glu Asn Tyr Cys Asn
80 50
82 <210> SEQ ID NO: 4
83 <211> LENGTH: 16
84 <212> TYPE: PRT
85 <213> ORGANISM: Artificial Sequence
87 <220> FEATURE:
88 <223> OTHER INFORMATION: Sequence is synthesized.
90 <400> SEQUENCE: 4
91 Arg Asn Cys Phe Glu Ser Val Ala Ala Leu Arg Arg Cys Met Tyr
92 1 5 10 15
94 Gly
97 <210> SEQ ID NO: 5
98 <211> LENGTH: 56
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
102 <220> FEATURE:
103 <223> OTHER INFORMATION: Residues observed in IGF-1 structure.
105 <400> SEQUENCE: 5
106 Glu Thr Leu Cys Gly Ala Glu Leu Val Asp Ala Leu Gln Phe Val
107 1 5 10 15
109 Cys Gly Asp Arg Gly Phe Tyr Phe Asn Lys Pro Thr Gly Tyr Gly
110 20 25 30
112 Ser Ser Thr Gly Ile Val Asp Glu Cys Cys Phe Arg Ser Cys Asp
113 35 40 45
115 Leu Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu
116 50 55

```

VERIFICATION SUMMARY

DATE: 07/10/2002

PATENT APPLICATION: US/10/066,009A

TIME: 13:07:39

Input Set : A:\P1869R1.txt

Output Set: N:\CRF3\07102002\J066009A.raw

L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date